Bumetanide

3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid · bumex · Lixil · pf159 · DONALD · burine · pf1593 · Bufenox

식별자 및 물리적 특성

CAS No.	28395-03-1
분자식	C17H20N2O5S
평균 분자량	364.4 g/mol
단동위원소 질량	364.10929292 g/mol
SMILES	CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
InChIKey	MAEIEVLCKWDQJH-UHFFFAOYSA-N
PubChem CID	2471
ChEMBL	CHEMBL1072
ChEBI	CHEBI:3213
EC No.	249-004-6
DTXSID	DTXSID5022699

화학 및 물리적 성질

XLogP	2.8
극성 표면적	127
수소 결합 공여자 수	3
수소 결합 수용자 수	7
회전 가능 결합 수	8
무거운 원자 수	25
형식 전하	0
복잡도	528
LogP(분배 계수)	2.6
용해도	>20 mg/mL (in base)2.57e-02 g/L>54.7 [ug/mL] (The mean of the results at pH 7.4)물에 거의 녹지 않으며, 아세톤과 알코올에 녹고, 염화메틸렌에는 약간 녹습니다. 알칼리 수산화물의 묽은 용액에 용해됩니다.
녹는점	230-231230 - 231 °C230-2310C
Physical Description	Solid
Dissociation Constants	3.833.6
Collision Cross Section	185.1 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]195.27 Å² [M+K]+ [CCS Type: TW168.69 Å² [M+H-H2O]+ [CCS Type: TW193.48 Å² [M+Na]+ [CCS Type: TW
끓는 점	571.2±60.0 °C(Predicted)
밀도	1.2812 (rough estimate)
굴절률	1.6510 (estimate)
저장 조건	2-8°C
물리적 상태	Solid
pKa(산도 계수)	pK1 3.6, pK2 7.7(at 25℃)
색상	흰색에서 밝은 노란색
용해도	에탄올(10mg/ml), DMSO(25mg/ml), 아세톤, 벤젠, 메탄올, 프로필렌 글리콜 및 물(<1mg/ml)에 용해됩니다.
주요 응용	의약품(소분자)
InChI	InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
InChIKey	MAEIEVLCKWDQJH-UHFFFAOYSA-N
SMILES	C(O)(=O)C1=CC(NCCCC)=C(OC2=CC=CC=C2)C(S(N)(=O)=O)=C1
EPA	Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- (28395-03-1)

화학적 성질

Crystalline Solid

안전 및 규제

GHS 분류	WarningH315 (75%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (75%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (75%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]H361d (25%): Suspected of damaging the unborn child [Warning Reproductive toxicity]P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
기타 안전 정보	IMAP assessments - Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-: Human health tier I assessmentIMAP assessments - Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-: Environment tier I assessment
Hazard Classes and Categories	Skin Irrit. 2 (75%)Eye Irrit. 2A (75%)STOT SE 3 (75%)Repr. 2 (25%)
유해 작용	The most common adverse events associated with bumetanide include hyperuricemia (characteristic of all loop diuretics), hypochloremia, hypokalemia, azotemia, and hyponatremia. Other less common adverse effects include hyperglycemia, increased serum creatinine, muscle weakness, and hearing impairment. Rare but significant or potentially life-threatening adverse reactions include hypotension (including orthostatic hypotension), encephalopathy (in instances of pre-existing hepatic disease), and renal failure. All loop diuretics exhibit potent diuresis capabilities, and excessive amounts can lead to significant diuresis with fluid and electrolyte lossclose medical supervision is necessary when administering these agents.
독성 요약	Extensive or too frequent dosage can lead to acute volume and electrolyte depletion, low circulatory volume with a possibility of vascular thrombosis, and embolism. Symptoms such as weakness, mental confusion, anorexia, lethargy, vomiting, and cramps may occur because of electrolyte depletion. Treatment is with the adequate replacement of fluids and electrolytes, such as adding potassium supplements or potassium-sparing diuretics in case of potassium depletion. Asymptomatic hyperuricemia and slight reversible elevations of BUN and creatinine may also occur, particularly associated with dehydration or patients with renal insufficiency. Bumetanide has shown an increase in urinary calcium with resultant hypocalcemia. Similarly, hypomagnesemia should be measured periodically.
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)BumetanideAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation	◉ Summary of Use during LactationIt is unknown if bumetanide is excreted into breastmilk. It should be avoided while breastfeeding a newborn because it may decrease milk flow or completely suppress lactation. Low doses in mothers whose lactation is well established are unlikely to suppress lactation.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and BreastmilkRelevant published information on bumetanide was not found as of the revision date. Intense diuresis, fluid restriction and breast binding have been used to suppress lactation immediately postpartum. The added contribution of the diuretic to the other measures, which are effective in suppressing lactation, has not been studied. No data exist on the effects of loop diuretics on established, ongoing lactation.
수질 위해 등급(WGK)	3
RTECS 번호	DG4910000
독성	LD50 i.v. in mice: 330 mg/kg (Oestergaard)
관세 코드	2935904000
저장 분류	11 - Combustible Solids

용도

Bumetanide is a diuretic.